Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam Radiation
- 1 August 1995
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 154 (2), 456-459
- https://doi.org/10.1016/s0022-5347(01)67073-3
Abstract
We demonstrate the 5-year survival rate for patients with prostate cancer treated by irradiation, the value of the conformal technique and prostate specific antigen (PSA) doubling times after irradiation. The outcome of 502 consecutive patients with stages T1 to T3 prostate cancer treated by irradiation alone is reported. PSA doubling times before and after failure are reported for 13 patients and posttreatment PSA doubling times are reported for 93 consecutive patients in whom radiation failed. The actuarial survival with biochemical freedom from disease (PSA nadir 1.5 or less not increasing) at 5 years was 44 percent for all patients, 50 percent for the conformal treatment group and 39 percent for the conventional therapy group. PSA doubling times after radiation failure were variable, with 42 percent greater than 12 months. The 5-year survival rate for patients with prostate cancer treated by irradiation is excellent. The conformal technique is superior to conventional therapy and there is no evidence that irradiation accelerates the growth rate of prostate cancer.Keywords
This publication has 13 references indexed in Scilit:
- Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.Journal of Clinical Oncology, 1995
- PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year resultsUrology, 1994
- Radical Radiation Therapy in the Management of Prostatic Adenocarcinoma: The Initial Prostate Specific Antigen Value as a Predictor of Treatment OutcomeJournal of Urology, 1994
- Patterns of care and rtog studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cureInternational Journal of Radiation Oncology*Biology*Physics, 1994
- The Value of Serial Prostate Specific Antigen Determinations 5 Years after Radiotherapy: Steeply Increasing Values Characterize 80% of PatientsJournal of Urology, 1993
- The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancerJAMA, 1993
- Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation TherapyJournal of Urology, 1991
- Carcinoma of the prostate Stage B and C: Lack of influence of duration of radiotherapy on tumor control and treatment morbidityInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Optimizing the radiation treatment and outcome of prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1985